Zurier R B, Sayadoff D M, Torrey A B, Rothfield N F
Arthritis Rheum. 1977 Mar;20(2):723-8. doi: 10.1002/art.1780200213.
NZB/NZW F1 hybrid mice were treated with pharmacologic doses of prostaglandin E1 (PGE1) (200 microng subcutaneously either once or twice daily) from 6 through 52 weeks of age. PGE1-treated mice were protected against development anemia, clinical nephritis, and death. At 52 weeks 18 of 19 treated mice were alive, wherase only 2 of 19 untretreated control mice were alive. None of the 10 mice treated with PGE1 twice daily exhibited significant (greater than 2+) proteinuria at 1 year of age. PGE1 treatment did not prevent development of antibodies to nuclear antigens. The data also suggest that survival of NZB/NZW mice is prolonged when treatment with PGE1 is begun at 24 weeks, an age at which mice already show evidence of nephritis. Thus all 6 mice treated with PGE1 (200 microng sc twice daily) from 24 weeks were alive at 52 weeks, whereas only 2 of 6 untreated control mice were alive. The mechanisms whereby PGE1 treatment influences the course of disease in NZB/NZW mice are not known.
从6周龄至52周龄，给NZB/NZW F1杂交小鼠皮下注射药理剂量的前列腺素E1（PGE1）（200微克，每日一次或两次）。接受PGE1治疗的小鼠可预防贫血、临床肾炎的发生以及死亡。在52周时，19只接受治疗的小鼠中有18只存活，而19只未接受治疗的对照小鼠中只有2只存活。每日接受两次PGE1治疗的10只小鼠在1岁时均未出现显著的（大于2+）蛋白尿。PGE1治疗不能阻止抗核抗原抗体的产生。数据还表明，若在24周龄（此时小鼠已出现肾炎迹象）开始用PGE1治疗，NZB/NZW小鼠的存活期会延长。因此，从24周开始接受PGE1（200微克皮下注射，每日两次）治疗的所有6只小鼠在52周时均存活，而6只未接受治疗的对照小鼠中只有2只存活。PGE1治疗影响NZB/NZW小鼠疾病进程的机制尚不清楚。
